Retatrutide Dosing & Protocols — Research Reference

Retatrutide is a triple agonist (GLP-1 / GIP / glucagon receptor) studied in metabolic and body-composition research. Phase II trial literature provides the dosing-tier framework compiled here.

Reconstitution for Research

Retatrutide is supplied lyophilized. Standard practice reconstitutes 10–20 mg with 1–2 mL bacteriostatic water for concentrated weekly dosing. Refrigerated stability after reconstitution typically extends 28+ days per COA.

Reference Dose Ranges in Published Research

| Research model tier | Typical range | Notes | |---|---|---| | Initiation | 2 mg/week × 4 weeks | Conservative entry due to triple-receptor signal intensity | | Intermediate | 4–8 mg/week | Most-cited metabolic-research maintenance window | | High tier | 8–12 mg/week | Body-composition research; tolerability monitoring required |

Scheduling

Weekly subcutaneous, single-day-of-week schedule with site rotation. Steady-state plasma at ~4 weeks. The glucagon-receptor component contributes to higher resting energy expenditure markers vs. pure incretin agonists.

Cycling in the Published Literature

Continuous-administration paradigm dominates the published literature. Discontinuation produces faster metabolic-marker regain than semaglutide due to the additional glucagon-axis effect, per published trial follow-up data.

Common Research Endpoint Markers

Glycemic: HbA1c, fasting glucose, insulin. Body composition: weight, fat-mass markers, lean-mass preservation. Energy expenditure markers track the glucagon-receptor signal. Hepatic markers (ALT, AST) and lipid panel are tracked closely due to triple-receptor pharmacology.

Common Research Pairings

Retatrutide is most often studied as monotherapy due to its triple-agonist breadth. Limited combination research with cagrilintide for amylin-pathway complementarity is emerging.

Storage & Stability

Lyophilized stable at 2–8 °C protected from light. Reconstituted refrigerated; avoid freeze-thaw.

Frequently Asked Questions

How does the glucagon-receptor component change dosing strategy?

Glucagon-receptor agonism increases resting energy expenditure but also influences hepatic glucose output and lipid metabolism. Researchers titrate more cautiously and monitor hepatic markers more frequently than with pure GLP-1 agonists.

Is retatrutide more potent than tirzepatide?

Per published Phase II data, retatrutide shows larger weight-marker effects at top doses than tirzepatide. Direct head-to-head trials are not yet published.

Research-Use Disclosure

All content is provided strictly for laboratory research purposes. Compounds discussed are research chemicals and are not for human or veterinary consumption. Dosing ranges referenced below are summaries of published preclinical and clinical research literature compiled for laboratory reference only — they are not medical recommendations.